The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.
Tomoyuki SatakeChigusa MorizaneYuta MarukiAkihiro OhbaYoshikuni NagashioShunsuke KondoSusumu HijiokaHideki UenoTakuji OkusakaPublished in: International journal of clinical oncology (2022)
) in non-DV patients.